



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of:) Examiner: Angell, Jon E.
Avi J. ASHKENAZI, et al..)
Application Serial No. 09/978,564) Art Unit: 1635
Filed: October 16, 2001) Confirmation No. 5282
For: **SECRETED AND**) Attorney's Docket No. 39780-2630
TRANSMEMBRANE) P1C25
POLYPEPTIDES AND NUCLEIC) **Customer No. 35489**
ACIDS ENCODING THE SAME)

EXPRESS MAIL LABEL NO. EV 582 622 586 US
Date Mailed: SEPTEMBER 29, 2005

AMENDMENT AND RESPONSE TO OFFICE ACTION

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed on June 29, 2005 (Paper No./Mail Date 20050616), in connection with the above-identified patent application, please enter the following amendments, and consider the following arguments. This response is timely filed within the three month shortened statutory period set for the response.

Also filed herewith is an Information Disclosure Statement providing sufficient identifying information regarding the BLAST results. Applicants respectfully request that the information listed in the Information Disclosure Statement be considered by the Examiner and be made of record in the above-identified application.

The present Amendment and Response is further accompanied by the submission of a non-executed Declaration under 37 C.F.R. §1.131, the consideration of which is respectfully requested. The executed Declaration signed by all of the inventors will be submitted to the PTO shortly.

In addition, enclosed herewith is an Amendment under 37 C.F.R. §1.48(b) to correct the inventorship in the present application, the consideration of which is respectfully requested.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims begin on page 12 of this paper.

Remarks/Arguments begin on page 13 of this paper.